David A. Siegel Atreca, Inc. Transaction History

Two Sigma Advisers, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.56 - $3.25 $27,456 - $57,200	-17,600 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.61 - $5.2 $152,628 - $492,960	-94,800 Reduced 84.34%	17,600 $56,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $322,588 - $706,996	112,400 New	112,400 $341,000
Q2 2021 Aug 16, 2021	SELL	$7.82 - $13.8 $136,068 - $240,120	-17,400 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$13.0 - $19.34 $226,200 - $336,516	17,400 New	17,400 $267,000

1.04M

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.